FindTrial
Sign In

DNA repair assay for tumor response prediction in cervical cancer to radiotherapy

Establishing biochip-based cell free DNA repair assay for cancer treatment outcome prediction. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/069714
Enrollment
100
Registered
2024-07-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed with cervical cancer. 2. Planned to undergo chemo-radiotherapy. 3. Age over 18 years old. 4. Able to give informed consent.

Exclusion criteria

Exclusion criteria: 1. prior cancer surgery 2. secondary cancer 3. metastasis 4. non-conventional treatment

Design outcomes

Primary

MeasureTime frame
Establishment of a functional DSB repair fluorescent assay on a chip that provides a rapid and reliable method for detecting DNA damage and repair activity in cells, compared to traditional methods.Timepoint: One time point—

Secondary

MeasureTime frame
Predictive biomarkers for cancer treatment outcomes, offering insights into personalized medicine and the improvement of patient care.Timepoint: One time point—

Countries

India

Contacts

Public ContactKamalesh D Mumbrekar

Manipal School of Life Sciences, MAHE, Manipal. Manipal

kamalesh.m@manipal.edu9880100901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026